Surgical treatment decision and clinical value of molecularly defined renal carcinoma with highly aggressive behavior
10.3969/j.issn.1009-8291.2024.04.001
- VernacularTitle:高侵袭性特殊分子特征肾细胞癌的外科治疗决策及其价值（“大家泌尿网”观看手术视频）
- Author:
Xiang LI
1
;
Lijing XU
1
;
Guangxi SUN
1
;
Jindong DAI
1
Author Information
1. Department of Urology, West China Hospital, Sichuan University, Chengdu 610041, China
- Publication Type:Journal Article
- Keywords:
molecularly defined renal carcinoma;
surgical treatment decision;
cytoreductive nephrectomy;
highly aggressive;
metastatic renal cell carcinoma
- From:
Journal of Modern Urology
2024;29(4):293-297
- CountryChina
- Language:Chinese
-
Abstract:
Molecularly defined renal carcinoma is a pathologic subtype of renal cell cancer (RCC) with a definite driver gene, which was first proposed in the 2022 WHO classification of tumors of the urinary system and male reproductive organs. The fumarate hydratase-deficient renal cell carcinoma and SMARCB1-deficient renal medullary carcinoma are highly aggressive and lethal subtypes. Due to the low incidence and lack of research on the mechanism, there is almost no effective treatment for these aggressive RCC subtypes. Cytoreductive nephrectomy or metastasectomy are important methods to improve the survival and quality of life of metastatic RCC patients under effective systemic therapy. However, for the highly aggressive RCC, the clinical value of the above surgical strategies is still unclear. In this review, we will discuss these problems in order to provide reference for the improvement of prognosis for patients with highly aggressive RCC subtypes.
